Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies

  • Taylor H
  • Giudice L
  • Lessey B
  • et al.
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVE: To evaluate the safety and efficacy of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, as compared to placebo in the management of moderate/severe endometriosis-associated pain (EAP). DESIGN: These were two similar, double-blind, randomized, placebocontrolled, multicenter, 6-month, phase 3 studies (Studies 1 [North America] and 2 [global]) evaluating two doses of elagolix (150mg once daily [QD] and 200mg twice daily [BID]). Each study has an ongoing 6-month extension study. MATERIALSANDMETHODS: Participants were 18-49 year-old women with surgically diagnosed endometriosis within prior 10 years and moderate/ severe EAP. The co-primary efficacy endpoints were the proportion of responders (controlled for rescue analgesic use) at month 3 based on daily dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP) scores recorded in an electronic diary. The clinically meaningful response for DYS and NMPP was determined with a receiver operating characteristics analysis using the Patient Global Impression of Change (PGIC, ''much'' or ''very much'' improved) as the anchor. The proportion of DYS and NMPP responders at month 6 was a secondary endpoint. Safety assessments included adverse events (AE), clinical laboratory tests, and changes in bone mineral density and endometrium. RESULTS: In Studies 1 and 2 respectively, 871 and 815 participants were randomized and treated; 653 (75%) and 631 (77%) completed. Compared to placebo, each dose of elagolix resulted in a significantly greater proportion of responders for DYS and NMPP, at months 3 (Table) and 6. Hot flush (mostly mild/moderate), headache and nausea were the most common AEs for elagolix- treated participants (Table). A dose-dependent increase in serum lipids and decrease in BMD were observed with elagolix treatment. There were no adverse endometrial findings. CONCLUSIONS: In women with EAP, elagolix showed dose-dependent superiority compared to placebo in reducing DYS and NMPP over 6 months in two large studies. The safety/tolerability profile was consistent with dosedependent hypoestrogenic effects.

Cite

CITATION STYLE

APA

Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M., Kotarski, J., Williams, L. A., … Jain, R. I. (2016). Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies. Fertility and Sterility, 106(3), e271. https://doi.org/10.1016/j.fertnstert.2016.07.780

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free